Image source: The Motley Fool. Merck (NYSE: MRK) Q1 2024 Earnings Call Apr 25, 2024, 9:00 a.m. ET Operator Continue reading
motleyfoolusx:mrk
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales increased 9% year-over-year to $15.8 billion, mainly reflecting sustained growth across the oncology and vaccine ...
alphastreetusx:mrk
In biopharma, it sometimes makes sense for companies to spend a lot of money on buying or developing technical capabilities that seem to be counterproductive at first glance. For instance, on April 5, Merck (NYSE: MRK) spent $208 million to acquire a business called Abceutics, which is developing a technology ...
motleyfoolusx:mrk
According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine may have another blockbuster drug in the works, this time a personalized cancer vaccine (PCV) for head ...
motleyfoolusx:mrnausx:mrk
